Head to head
ACE-031 against Bimagrumab
Two activin receptor blockers with different endings. ACE-031 was halted over vascular safety signals in muscular dystrophy; bimagrumab reached a 507 person randomised phase 2 in obesity and is being developed for body composition.
Column A
ACE-031ACE-031 (soluble activin receptor type IIB)
A myostatin/activin decoy studied for muscular dystrophy whose trials were halted over vascular safety signals.
Column B
BimagrumabBimagrumab (anti-activin receptor antibody)
A muscle-preserving antibody that blocks activin receptors to reduce fat while increasing lean mass, being studied alongside GLP-1 drugs.
Side by side, on the facts we can check
| Attribute | ACE-031 | Bimagrumab |
|---|---|---|
| Category | Muscle & Performance | Metabolic |
| FDA status | Not FDA-approved; development halted on safety grounds | Investigational for obesity / body composition; Phase 2 BELIEVE published 2026 |
| Half-life | Days (fusion protein) | Weeks (antibody) |
| Molecular weight | ~78,000 Da | About 150 kDa (IgG1 monoclonal antibody; KEGG lists the full heavy and light chain sequences but no mass) |
| Mechanism | Binds and neutralizes myostatin and activin before they can signal, releasing their inhibition of muscle growth. | Blocks activin type II receptors, neutralizing myostatin and activin signaling to build muscle and reduce fat mass. |
| Human studies cited | 2 | 2 |
| Legal status, US | Not approved; research use only | Investigational, not approved |
Frequently asked questions
What is the difference between ACE-031 and Bimagrumab?
ACE-031: A myostatin/activin decoy studied for muscular dystrophy whose trials were halted over vascular safety signals. Bimagrumab: A muscle-preserving antibody that blocks activin receptors to reduce fat while increasing lean mass, being studied alongside GLP-1 drugs.
Which has stronger research evidence, ACE-031 or Bimagrumab?
This database does not grade compounds. It counts what was run in people: 2 of the 2 studies cited on the ACE-031 profile were human work, against 2 of 2 for Bimagrumab. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are ACE-031 and Bimagrumab FDA-approved?
ACE-031: Not FDA-approved; development halted on safety grounds. Bimagrumab: Investigational for obesity / body composition; Phase 2 BELIEVE published 2026.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.